2 edition of Economic evaluation of drug eluting stents found in the catalog.
Economic evaluation of drug eluting stents
by Canadian Coordinating Office for Health Technology Assessment in Ottawa
Written in English
|Statement||Nicole Mittmann ... [et al.].|
|Series||Technology report -- issue 53., Technology report (Canadian Coordinating Office for Health Technology Assessment) -- issue 53.|
|Contributions||Mittmann, Nicole, 1967-, Canadian Coordinating Office for Health Technology Assessment.|
|The Physical Object|
|Pagination||x, 61 p. :|
|Number of Pages||61|
Drug-eluting stents (DES) were considered a breakthrough technology when they were introduced in Since their introduction, they have been studied in over 50 randomized clinical trials that have clearly shown them to be safe and efficacious in the short and medium term.[1,2] They were developed to reduce the incidence of clinical restenosis [or target vessel revascularization (TVR)]and. Hill RA, Boland A, Dickson R, et al., Drug eluting stents: a systematic review and economic evaluation, Health Technol Assess, ;– Colmenarez HJ, Escaned J, Fernandez C, et al., Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta analysis, J Am Coll Cardiol Cited by: 3.
Meril Life Sciences Pvt. Ltd has become the first Indian stent maker to receive a rare exemption from government-set price caps. In a first, India’s drug price regulator on February 25 granted Gujarat based firm Meril Life Sciences an exemption from price controls for a stent it developed three years ago. This means that the firm has provided adequate justification to the government for Author: Teena Thacker. Methods. In this randomised single-blind trial, we recruited patients from 44 centres in nine countries. Patients were eligible if they were aged 75 years or older; had stable angina, silent ischaemia, or an acute coronary syndrome; and had at least one coronary artery with a stenosis of at least 70% (≥50% for the left main stem) deemed eligible for percutaneous coronary intervention (PCI).Cited by:
() Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial. Catheter Cardiovasc Interv – Cited by: 5. Stents with biodegradable polymers have not been shown to be superior to everolimus-eluting stents. Bioabsorbable scaffolds have not demonstrated better outcomes than current standard treatment with second-generation drug-eluting stents, but have showed a .
The London System
short guide to Great Britain.
history of the Argentine Republic
The Ladies repository
Prices of Agricultural Products and Selected Inputs in Europe and North America 1988 89/E 90 II E 5 (Annual ECE/FAO Price Review)
Plates of the arteries of the human body
Liquidity and the threat of fraudulent assets
State Museum of Oriental Art
few thoughts for a young man
Collection of hut and poll tax.
Citizens and paupers
White pines and fires
Bare metal stents (BMS) were introduced in to reduce restenosis. Drug eluting stents (DES) are a technological advance on BMS. They are a combination of a wire mesh stent to prop open the artery and a coating that delivers a drug locally to decrease restenosis at the stent site.
Technology Name Drug eluting stents Disease or Condition Patients with coronary artery disease commonly undergo balloon angioplasty to unblock narrowed arteries carrying blood to the heart. However, a frequent consequence of the treatment is re-narrowing (restenosis) of.
Meta-analysis of RCTs of DES versus BMS. All 17 RCTs identified were included for at least one outcome in the meta-analysis. A range of eluting agents were studied: paclitaxel (n = 11), sirolimus (n = 5), everolimus (n = 1) and ABT (n = 1). One study included three arms, comparing paclitaxel, sirolimus and non-eluting -up extended to 3 years for paclitaxel and sirolimus Cited by: COVID Resources.
Reliable information about the coronavirus (COVID) is available from the World Health Organization (current situation, international travel).Numerous and frequently-updated resource results are available from this ’s WebJunction has pulled together information and resources to assist library staff as they consider how to handle coronavirus.
Economic Evaluation of Sirolimus-Eluting Stents Article (PDF Available) in Canadian Medical Association Journal (3) March with 82 Reads How we measure 'reads'.
Kuukasjarvi P, Rasanen P, Malmivaara A, Aronen P, Sintonen H. Economic evaluation of drug-eluting stents: a systematic literature review and model-based cost-utility analysis. International Journal of Technology Assessment in Health Care ; 23(4): Economic evaluation of drug eluting stents: Cost-utility analysis Article in Value in Health 9(6) November with 52 Reads How we Economic evaluation of drug eluting stents book 'reads'.
This review assessed the clinical effectiveness of drug-eluting coronary artery stents in percutaneous coronary intervention in patients with coronary artery disease and concluded that they should be targeted at the subgroups of patients with the highest risks of requiring reintervention.
A number of areas were highlighted for further research. The conclusions are likely to be by: Genre/Form: Electronic books: Additional Physical Format: Print version: Mittmann, N. Drug eluting stents: an economic evaluation.
Ottawa: Canadian Coordinating Office for. Background: There is only limited information about cost‐effectiveness of drug‐eluting compared with bare metal stents (BMS) over a time horizon of more than 1 year.
Methods and Results: We developed a Markov model based on clinical outcome data from a meta‐analysis including 17 randomized controlled trials comparing drug‐eluting versus BMS with a minimum follow‐up of 1 (n = Cited by: A drug-eluting stent (DES) is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary arteries that slowly releases a drug to block cell proliferation.
This prevents fibrosis that, together with clots (), could otherwise block the stented artery, a process called stent is usually placed within the peripheral or coronary artery by an ICDCM: Preclinical Evaluation of Drug-Eluting Stents for Peripheral Applications Recommendations From an Expert Consensus Group Schwartz et al Preclinical Evaluation of Drug-Eluting Stents especially if the drug used is known to be toxic to certain types of tissues and cells.
What reimbursement for coronary revascularization with drug-eluting stents. Eur J Health Econ. ; 5: – Crossref Medline Google Scholar; 51 Ikeda S, Kobayashi M. Economic evaluation of drug-eluting stents in Japan. Keio J Med. ; 15– Crossref Medline Google ScholarCited by: Drug-eluting stents: a systematic review and economic evaluation: Hill R A, Boland A, Dickson R, Dundar Y, Haycox A, McLeod C, Mujica Mota R, Walley T, Bagust A CRD summary.
This review assessed the clinical effectiveness of drug-eluting coronary artery stents in percutaneous coronary intervention in patients with coronary artery disease and. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
J Am Coll Cardiol ; Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.
Lancet ; Drug-eluting coronary stents can help prevent plaque buildup, promote good blood flow to your heart, and relieve chest pain. They may also lower your chances of having a heart : Ann Pietrangelo. Emilio B. Lobato MD, in Essentials of Cardiac Anesthesia for Noncardiac Surgery, Drug-Eluting Stents.
Drug-eluting stents (DESs) consist of a metallic stent platform coated with a polymer carrier vehicle that stores an antiproliferative agent. The carrier releases the drug in a gradual and controlled fashion (elution), allowing local diffusion into the vascular tissue, thus preventing.
Economic Evaluation of the Use of Drug-Eluting Stents versus Bare-Metal Stents in Adults with Ischemic Cardiomyopathy Requiring Angioplasty Belinda González-Díaz1, Juan Garduño-Espinosa2, Guillermo Salinas-Escudero3, Alfonso Reyes-López3 and Víctor Granados-García4*. It blocks protein synthesis, cell cycle progression and migration by inhibiting mammalian target of rapamycin.
7 Its better kinetics and wider therapeutic index are the reasons why the antirestenotic efficacy of sirolimus-eluting stents are higher than paclitaxel-eluting stents. 8,9 The antirestenotic efficacy of these drugs is the reason new Cited by: 9.
GLOBAL MARKET PERSPECTIVE Table World Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of. Eisenstein EL, Leon MB, Kandzari DE, et al. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT] Eluting Coronary Stent System Versus the Cypher Sirolimus.Novel stent and drug elution technologies EVIEWR To address concerns of late and very late stent thrombosis associated with first generation drug-eluting stent technology, novel approaches are being tested including stents with bioabsorbable polymers (including Biomatrix Flex™, Nobori™ and Synergy™), polymer-free drug delivery systems Cited by: 4.
The Global Peripheral Drug-Eluting Stents Market is likely to gain impetus from a rise in the rates of tobacco consumption. According to an upcoming report by Fortune Business Insights, titled.